Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations

Haematologica

Volumn 92, Issue 6, 2007, Pages 795-802

  Largo, Cristina ^a   Saéz, Borja ^b   Alvarez, Sara ^a   Suela, Javier ^a   Ferreira, Bibiana ^a   Blesa, David ^a   Prosper, Felipe ^c   Calasanz, M Jose ^b   Cigudosa, Juan C ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Amplification; ArrayCGH; Homozygous deletion; Hyperdiploid; Multiple myeloma

Indexed keywords

IMMUNOGLOBULIN; SYNDECAN 1;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER GENETICS; CHROMOSOME DUPLICATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHROMOSOME XQ; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DATA ANALYSIS; DIPLOIDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FUNCTION; GENOME; HOMOZYGOSITY; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; CHROMOSOME ABERRATION; DNA MICROARRAY; GENE DOSAGE; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CHROMOSOME ABERRATIONS; FEMALE; GENE DOSAGE; GENE REARRANGEMENT; GENOME, HUMAN; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SYNDECAN-1; TRANSLOCATION, GENETIC;

EID: 34347214487     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11052     Document Type: Article

References (23)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-73.
2. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
4. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
5. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20:807-13.
6. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91:3007-10.
7. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004;104:2661-6.
8. Rao PH. Comparative genomic hybridization for analysis of changes in DNA copy number in multiple myeloma. Methods Mol Med 2005; 113:71-83.
9. Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I, et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006; 91:184-91.
10. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA, et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002;98:470-4.
11. Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 2004;101:17765-70.
12. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-25.
13. Rodriguez-Perales S, Martinez-Ramirez A, de Andres SA, Valle L, Urioste M, Benitez J, et al. Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet 2004;148:35-43.
14. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 1998;92:1743-8.
15. Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, Lohman K, et al. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1200-4.
16. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8.
17. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12:960-9.
18. Garcia JL, Hernandez JM, Gutierrez NC, Flores T, Gonzalez D, Calasanz MJ, et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003;17:2016-24.
19. Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303-16.
20. Cassia R, Moreno-Bueno G, Rodriguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003;201:589-95.
21. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-94.
22. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004;165:71-81.
23. Liebisch P, Viardot A, Bassermann N, Wendl C, Roth K, Goldschmidt H, et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 2003;122:193-201.